» Articles » PMID: 33635862

Elucidating the Impact of Obesity on Hormonal and Metabolic Perturbations in Polycystic Ovary Syndrome Phenotypes in Indian Women

Overview
Journal PLoS One
Date 2021 Feb 26
PMID 33635862
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Polycystic ovary syndrome is a complex endocrinopathy with heterogeneous presentation and multifactorial etiology. We have undertaken this case-control study to compare metabolic and endocrine characteristics in different phenotypic subgroups of women with PCOS and the impact of obesity on them. Women with PCOS (n = 489) were classified into 4 phenotypes according to Rotterdam criteria. Comparisons of clinical, biochemical and hormonal parameters were performed across all phenotypic groups of PCOS and with controls (n = 270) by Welch's ANOVA with subsequent Games-Howell post-hoc test. We found maximum prevalence of normoandrogenic phenotype D, which is milder form of PCOS in terms of insulin resistance, gonadotropin levels and dyslipidemia, followed by phenotype A, in our total study population. After classification of the study group into lean and obese groups, only few insulin and lipid-related traits showed marked differences between phenotypes. Further, we noted that obese women showed adverse metabolic but not androgenic traits compared to lean counterparts in the same phenotype. Metabolic syndrome frequency is increased in hyperandrogenic phenotypes with HDL-C and waist circumference being most predominant contributing factors in total, lean and obese groups. We demonstrate that in our study population there is greater occurrence of phenotype D of PCOS. Our study highlights the importance of clinicians concurrently employing Rotterdam criteria along with obesity status for ascertaining accurate PCOS status and formulating suitable therapeutic intervention.

Citing Articles

Clinical-exome sequencing unveils the genetic landscape of polycystic ovarian syndrome (PCOS) focusing on lean and obese phenotypes: implications for cost-effective diagnosis and personalized treatment.

Dhar S, Bhattacharjee P Sci Rep. 2024; 14(1):24468.

PMID: 39424910 PMC: 11489695. DOI: 10.1038/s41598-024-75719-0.


PCOS phenotype focus: phenotype D under the magnifying glass.

Myers S, Oliva M, Nordio M, Unfer V Arch Gynecol Obstet. 2024; 309(6):2307-2313.

PMID: 38502188 DOI: 10.1007/s00404-024-07408-2.


Comparative Study of Insulin Sensitivity and Resistance and Their Correlation with Androgens in Lean and Obese Women with Polycystic Ovary Syndrome.

Misra S, Gada J, Dhole C, Varthakavi P, Bhagwat N Reprod Sci. 2023; 31(3):754-763.

PMID: 37848646 DOI: 10.1007/s43032-023-01374-x.


Delineating the role of single-nucleotide polymorphism of CYP19 gene on aromatase activity in South Indian women with polycystic ovary syndrome.

Hegde P, Shetty S, Shetty P, Manjeera L, Shetty D, Kumari S J Genet Eng Biotechnol. 2023; 21(1):87.

PMID: 37603197 PMC: 10441965. DOI: 10.1186/s43141-023-00540-7.


Therapeutic effects of aqueous extract of bioactive active component of on the ovarian-uterine and hypophysis-gonadal axis in rat with polycystic ovary syndrome: Histomorphometric evaluation and biochemical assessment.

Adelakun S, Ukwenya V, Peter A, Siyanbade A, Akinwumiju C Metabol Open. 2022; 15:100201.

PMID: 35958118 PMC: 9361322. DOI: 10.1016/j.metop.2022.100201.


References
1.
Solomon C, Hu F, Dunaif A, Stampfer M, Willett W, Speizer F . Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002; 87(5):2013-7. DOI: 10.1210/jcem.87.5.8471. View

2.
Legro R . Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012; 30(6):496-506. PMC: 3649566. DOI: 10.1055/s-0032-1328878. View

3.
Melo A, Vieira C, Romano L, Ferriani R, Navarro P . The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Reprod Sci. 2011; 18(12):1230-6. DOI: 10.1177/1933719111414205. View

4.
Abruzzese G, Cerrrone G, Gamez J, Graffigna M, Belli S, Lioy G . Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome. Horm Metab Res. 2016; 49(1):23-29. DOI: 10.1055/s-0042-113463. View

5.
Ganie M, Marwaha R, Dhingra A, Nisar S, Mani K, Masoodi S . Observation of phenotypic variation among Indian women with polycystic ovary syndrome (PCOS) from Delhi and Srinagar. Gynecol Endocrinol. 2016; 32(7):566-70. DOI: 10.3109/09513590.2016.1141879. View